Novavax COVID-19 vaccine elicits robust immune response in early trial
No serious adverse events were reported and safety follow-up continues, Novavax said after the COVID-19 vaccine trial results.
Full Article
Novavax COVID-19 vaccine elicits robust immune response in early trial
DNA
0 shares
1 views
You might like
Related news coverage
Russia in touch with India for collaboration to manufacture COVID-19 vaccine Sputnik V: Health Ministry
Mid-Day
In a significant development related to the *COVID-19 *vaccine, Russia has expressed its willingness to the Indian government for..
-
Coronavirus | Oxford COVID vaccine data could go before regulators this year: Director
Hindu
-
Covid update: Pfizer says it will have the ability to supply 1.3bn vaccine doses by the end of next year (if trials and approvals go to plan)
Proactive Investors
-
Pfizer coronavirus vaccine passes early stage trials
Proactive Investors
-
Coronavirus vaccine candidate induces immune response, trial results indicate
Belfast Telegraph
Advertisement
More coverage
Dow jumps 373 points as stimulus hopes blot out weak jobs data
Business Insider
· *US stocks climbed on Wednesday as investors maintained optimism for a bipartisan stimulus measure.*
· *Democrats and the..
